Publication | Closed Access

A novel bispecific ligand-directed toxin designed to simultaneously target EGFR on human glioblastoma cells and uPAR on tumor neovasculature

Drug TargetingMedicineHuman Glioblastoma CellsTumor NeovasculatureTumor TargetingAnti-cancer AgentCancer TreatmentRadiation OncologyPharmacologyGliomaTumor BiologyDrug Discovery